Redmile Group, LLC Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001425738

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidHealth TiltHigh Turnover how tags are computed

Q1 2024 · 77 positions · Total reported value $2.72B · Top-10 concentration 41.9% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 69.2% · 4 new · 23 cut · 0 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q1 2026 → Q2 2026): +21.6% · vs SPY +6.8% · Prev Value $1.51B — last quarter positions weighted by this quarter price moves · ranking

In its Q1 2024 13F filing, Redmile Group, LLC disclosed 77 equity positions with a combined reported value of $2.72B. The filing implies a moderately concentrated portfolio: its ten largest positions account for 41.9% of reported value. HoldingsHub classifies the profile as Mid / Health Tilt / High Turnover.

The largest disclosed positions as of Q1 2024 were KRYS ($268.36M), FOLD ($156.17M), IMNM ($120.67M). By sector, the heaviest allocations are Health Care 79.1%, Consumer Discretionary 0.8%. Versus the prior quarter, allocation shifted toward Health Care (+25.4pp) and away from Other (-25.3pp).

Versus the prior quarter, Redmile Group, LLC opened 4 new positions, trimmed 23 and fully exited 0, a turnover rate of 69.2% of positions. The portfolio's overlap with the prior quarter was 71% of names.

The largest new positions opened in Q1 2024 were SLN ($43.80M), FDMT ($40.19M), KROS ($36.58M).

Of the 8 positions fully exited versus the prior quarter, the largest were IMGN ($486.97M), RYZB ($115.49M), SPY ($67.73M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q1 2024)

  • SLN SILENCE THERAPEUTICS PLC · $43.80M
  • FDMT 4D MOLECULAR THERAPEUTICS IN · $40.19M
  • KROS KEROS THERAPEUTICS INC · $36.58M
  • CI THE CIGNA GROUP · $23.77M
  • ARDX ARDELYX INC COM · $16.02M
  • BOLD BOUNDLESS BIO INC · $15.87M
  • ICLR ICON PUB LTD CO · $12.41M
  • PGNY Progyny Inc · $12.24M

Fully Exited (vs previous quarter)

  • IMGN IMMUNOGEN INC · prev qtr: $486.97M
  • RYZB RAYZEBIO INC · prev qtr: $115.49M
  • SPY STATE STR SPDR S&P 500 ETF T · prev qtr: $67.73M
  • CRL CHARLES RIV LABS INTL INC · prev qtr: $20.52M
  • SNCE SCIENCE 37 HOLDINGS INC · prev qtr: $5.29M
  • MDVLQ MEDAVAIL HOLDINGS INC · prev qtr: $3.05M
  • SLGC SOMALOGIC INC · prev qtr: $938.22K
  • NVTAQ INVITAE CORP · prev qtr: $923.92K

Insider Transactions (Form 4)

Latest Redmile Group, LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

Transaction date Activity Security Shares Price Filing
2026-08-06 Buy Attovia Therapeutics, Inc. 400,000 $17.00 SEC filing
2026-08-06 Buy Attovia Therapeutics, Inc. 200,000 $17.00 SEC filing
2026-08-06 Conversion Attovia Therapeutics, Inc. 782,854 — SEC filing
2026-07-22 Tax payment Atara Biotherapeutics, Inc. 60 — SEC filing
2026-07-22 Opt exercise Atara Biotherapeutics, Inc. 195,211 — SEC filing
2026-04-20 J FATE THERAPEUTICS INC 8,977,624 — SEC filing

All insider transactions →

Fund Profile

Redmile Group, LLC, based in Larkspur, CA, United States, files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q2 2026) lists 39 positions worth $1.49B in total. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Firm Snapshot

  • Headquarters: LARKSPUR, CA, United States
  • SEC registration: 801-67747 (status: Approved), registered 2007-04-19
  • Regulatory AUM (Form ADV): $4.70B as of 2026-08-28
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 20 private funds, of which 10 hedge funds
  • Website: redmilegroup.com

Portfolio Structure

  • 39 positions · $1.49B reported value (Q2 2026)
  • Top 10 holdings = 73.5% of reported value
  • Largest position: SRRK (SCHOLAR ROCK HLDG CORP) at 15.9%
  • Average position size: $38.19M

Sector Tilt

  • Health Care 100.0%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q2 2026: 4 new, 5 added, 23 reduced
  • 7 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

Redmile Group Rebalancing Analysis (2026-Q2) 1. Overall Direction & Market View The fund is taking a cautious stance, significantly reducing positions in most top holdings while maintaining a concentrated focus on healthcare/biotech, suggesting potential profit-taking or rebalancing rather than a major sector shift. 2. Key Moves - Major reductions: SRRK (-52.5%), NRIX (-47.3%), ANNX (-18.4%), ABSI (-18.3%), IMNM (-11.6%) - Only addition in top-10: STTK (+24.4%) - 4 new positions added (not specified) - RGNX held steady 3. Portfolio Structure - Active management with frequent position adjustments - Extreme sector concentration (100% healthcare/biotech in top-10) - Moderate risk appetite with focus on small/mid-cap biotech companies - Recent reductions indicate some risk mitigation 4. Per-Holding Business Identification - SRRK: Scholar Rock - Biotechnology developing muscle-targeted therapies - KRYS: Krystal Biotech - Gene therapy for rare diseases - STOK: Stoke Therapeutics - Neurological disorder treatments - IMNM: Immunome - Antibody discovery and development - NRIX: Nurix Therapeutics - Targeted protein degradation therapies - ABSI: AbSci - Synthetic biology for antibody production - ANNX: Annexon - Neurodegenerative and ophthalmic disease treatments - RGNX: Regenxbio - Gene therapy using NAV technology platform - STTK: Shattuck Labs - Novel immunology therapies - NGNE: Neurogene - Gene therapy for neurological disorders 5. Style Summary The Redmile Group is actively trimming biotech positions while selectively increasing exposure to Shattuck Labs, maintaining a concentrated healthcare focus with cautious risk management.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice.

Sector Allocation

Health Care 79.1%
Materials 0.0%
Other 20.0%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 1.51M $268.36M 9.85%
9.85%
Reduce
2 13.26M $156.17M 5.73%
5.73%
Reduce
3 4.89M $120.67M 4.43%
4.43%
Add
4 6.42M $114.01M 4.18%
4.18%
Hold
5 13.17M $96.66M 3.55%
3.55%
Hold
6 4.55M $95.90M 3.52%
3.52%
Add
7 5.30M $83.32M 3.06%
3.06%
Add
8 1.73M $69.71M 2.56%
2.56%
Reduce
9 15.27M $68.56M 2.52%
2.52%
Hold
10 5.07M $68.49M 2.51%
2.51%
Add
11 16.38M $67.00M 2.46%
2.46%
Hold
12 4.48M $65.90M 2.42%
2.42%
Add
13 1.16M $63.62M 2.33%
2.33%
Reduce
14 1.88M $62.10M 2.28%
2.28%
Add
15 5.56M $58.50M 2.15%
2.15%
Reduce
16 1.04M $58.05M 2.13%
2.13%
Reduce
17 5.62M $50.20M 1.84%
1.84%
Hold
18 4.33M $48.24M 1.77%
1.77%
Add
19 935.25K $47.60M 1.75%
1.75%
Reduce
20 1.86M $46.95M 1.72%
1.72%
Add
21 8.25M $46.88M 1.72%
1.72%
Add
22 3.10M $46.15M 1.69%
1.69%
Add
23 2.03M $43.80M 1.61%
1.61%
New
24 922.68K $40.49M 1.49%
1.49%
Reduce
25 1.26M $40.19M 1.48%
1.48%
New
26 5.50M $39.46M 1.45%
1.45%
Hold
27 560.93K $38.42M 1.41%
1.41%
Reduce
28 896.45K $37.62M 1.38%
1.38%
Reduce
29 552.51K $36.58M 1.34%
1.34%
New
30 632.46K $35.70M 1.31%
1.31%
Reduce
31 969.62K $31.33M 1.15%
1.15%
Reduce
32 3.73M $30.47M 1.12%
1.12%
Reduce
33 262.37K $29.82M 1.09%
1.09%
Reduce
34 3.07M $29.65M 1.09%
1.09%
Add
35 87.25K $28.61M 1.05%
1.05%
Add
36 3.96M $26.63M 0.98%
0.98%
Add
37 2.26M $26.36M 0.97%
0.97%
Add
38 65.44K $23.77M 0.87%
0.87%
New
39 679.17K $22.27M 0.82%
0.82%
Reduce
40 1.60M $21.31M 0.78%
0.78%
Reduce
41 1.28M $18.19M 0.67%
0.67%
Hold
42 52.49K $17.51M 0.64%
0.64%
Reduce
43 31.22K $16.19M 0.59%
0.59%
Add
44 2.19M $16.02M 0.59%
0.59%
New
45 1.11M $15.87M 0.58%
0.58%
New
46 43.25K $15.48M 0.57%
0.57%
Reduce
47 5.76M $14.79M 0.54%
0.54%
Reduce
48 2.07M $14.52M 0.53%
0.53%
Add
49 36.95K $12.41M 0.46%
0.46%
New
50 320.86K $12.24M 0.45%
0.45%
New

FAQ

What did Redmile Group, LLC buy in 2024-Q1?

In its 2024-Q1 13F filing, Redmile Group, LLC reported 77 equity positions worth $2.72B in aggregate; its largest disclosed positions were KRYS ($268.36M), FOLD ($156.17M), IMNM ($120.67M).

How large is Redmile Group, LLC's portfolio?

Redmile Group, LLC reported $2.72B of long equity holdings across 77 positions as of 2024-Q1. Top-10 holdings account for 41.9% of reported value.

What is Redmile Group, LLC's investment style?

HoldingsHub classifies the portfolio as Mid / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/redmile/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →